Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Rating of “Hold” by Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned an average rating of “Hold” from the eight analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.75.

Several research analysts recently issued reports on INO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday, December 29th. UBS Group restated an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. Citigroup restated a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Green Alpha Advisors LLC lifted its stake in shares of Inovio Pharmaceuticals by 49.9% in the fourth quarter. Green Alpha Advisors LLC now owns 72,095 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 24,007 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 61,516 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Inovio Pharmaceuticals in the 3rd quarter valued at approximately $41,000. XTX Topco Ltd lifted its position in Inovio Pharmaceuticals by 855.5% in the 3rd quarter. XTX Topco Ltd now owns 210,567 shares of the biopharmaceutical company’s stock valued at $493,000 after acquiring an additional 188,529 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Inovio Pharmaceuticals by 468.7% during the 3rd quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock valued at $4,616,000 after purchasing an additional 1,625,653 shares during the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Stock Down 3.2%

NASDAQ INO opened at $1.51 on Friday. The firm has a market capitalization of $100.76 million, a PE ratio of -0.58 and a beta of 1.62. The stock’s 50 day moving average is $1.89 and its 200 day moving average is $2.02. Inovio Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. On average, research analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.